Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2020
2019
2018
Profitability Metrics
Gross Margin
26.45%
Operating Margin
125.27%
Net Margin
95.37%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
125.27%
Income Tax Rate
0.00%
EPS
1.2000000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
6.67
Working Capital
$-3.03M
Debt to Equity
0.41
Debt to Assets
28.78%
Equity Ratio
70.26%
Cash Flow Analysis
Operating Cash Flow Ratio
63.41%
Free Cash Flow Ratio
63.41%
CapEx to Revenue
0.00%
Dividends Paid
$29.52M
Stock Buybacks
$413.22K
Total Shareholder Returns
$29.93M
Cash Position Change
-24.29%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
148.02%
Net Income
144.53%
EPS
144.78%
Operating Income
162.17%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-32.67%
Operating Cash Flow
-60.01%
Free Cash Flow
-60.01%
Balance Sheet Health
Assets
-2.38%
Debt
-7.96%
Book Value per Share
0.91%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-7.02%
Shares Outstanding
-0.13%
Long Term Trends
3Y Revenue/Share
142.94%
5Y Revenue/Share
169.71%
3Y Dividend/Share
-11.73%
5Y Dividend/Share
-15.70%